Tweets
#RNL2023 Year in Review
COMPLETE-PsA: DMARDs for PsA!
LEF+MTX better than MTX alone, 78 total patients
PASDAS at week 16: 59% for MTX+LEF vs 34% MTX+PBO
More treatment discontinuations (10 vs 3) in combo group due to GI intolerance
@RheumNow https://t.co/3Al8PQmNli
Eric Dein @ericdeinmd ( View Tweet )
3 years 3 months ago
PMR classification criteria by @anisha_dua @RheumNow #RNL2023
Bursal and biceps tenosynovitis gets one point in PMR classification criteria. https://t.co/Lj1X9mkgBz
Nouf Al hemmadi @NoufAhmedAlham2 ( View Tweet )
3 years 3 months ago
Check out MothertoBaby fact sheets by the NIH and LactRX (by mother to baby) app for pregnancy, disease, and medications. Dr. C. Chambers highlighted this today at #RNL2023 @RheumNow
Dr. Rachel Tate @uptoTate ( View Tweet )
3 years 3 months ago
#RNL2023 Year in Review
Male response better than female response in patients with PsA in SELECT-PsA evaluating UPA/ADA.
More targeted studies needed
@RheumNow https://t.co/Z3kbM0e9A0
Eric Dein @ericdeinmd ( View Tweet )
3 years 3 months ago
Should we be measuring HCQ levels?
- note HCQ doses should be reconsidered in pts with CKD stage >2 w/ 4 fold higher odds of HCQ levels
- adjust dose for pts with renal impairment
@RheumNow #RNL2023 https://t.co/JvaRJKJRPv
Robert B Chao, MD @doctorRBC ( View Tweet )
3 years 3 months ago
#RNL2023 Year in Review
BE COMPLETE: P3 trial Bimekizumab for PsA in TNF inadequate responses at 16 weeks
160 mg BKZ SQ q4w vs PBO
ACR50 43%, PBO 7%
PASI 1000: BKZ 58.5% vs PBO 4.5%
Safety: oral candidiasis: 2.6% BKZ vs PBO 0%
@RheumNow https://t.co/bW00Wg6Cnf
Eric Dein @ericdeinmd ( View Tweet )
3 years 3 months ago
Talk to me about candidiasis. BKZ showed increased safety signals for candida infections. I fear infxns may be under reported (after approval and in use) if patients see other physicians for treatment vs their rheumatologist/derm. Thoughts on this signal? #RNL2023 @rheumnow https://t.co/UPA5oP9G49
Dr. Rachel Tate @uptoTate ( View Tweet )
3 years 3 months ago
Could MTX every other week dosing be an option in patients with stable disease..?
#RNL2023 https://t.co/EZRdQnuXjy
Dr Gurdeep Dulay @gurdeep_dulay ( View Tweet )
3 years 3 months ago
Urinary biomarkers in lupus nephritis
@RheumNow and Kavanaugh discusses new urinary biomarkers in lupus nephritis that correlates with histology!
#RNL2023 https://t.co/l1gQgFhviI
Nouf Al hemmadi @NoufAhmedAlham2 ( View Tweet )
3 years 3 months ago
Year in Review by Dr. Cush and Dr. Kavanaugh
Combo biologic therapy?
Phase II study from GI colleagues for UC
Guselkumab + golimumab
- no additional safety concerns
- improved clinical response
- extrapolate to rheumatology use?
#RNL2023 @RheumNow https://t.co/DirAovm1AX
Robert B Chao, MD @doctorRBC ( View Tweet )
3 years 3 months ago
✅ RheumNow Live 2023
#RNL2023 @RheumNow
Which adverse events ⬇️ can be expected by patients & their rheumatologists when using #hydroxychloroquine for #Lupus? https://t.co/9zP8aJ4cGq
Laurent ARNAUD @Lupusreference ( View Tweet )
3 years 3 months ago
TYK2 in plaque psoriasis By Eric Ruderman #RNL2023 @RheumNow
Safer?
No lab monitoring
And it works https://t.co/9Woen2q4hZ
Nouf Al hemmadi @NoufAhmedAlham2 ( View Tweet )
3 years 3 months ago
